stoxline Quote Chart Rank Option Currency Glossary
  
Myriad Genetics, Inc. (MYGN)
23.56  1.09 (4.85%)    06-12 16:00
Open: 24.01
High: 24.26
Volume: 830,255
  
Pre. Close: 22.47
Low: 22.95
Market Cap: 2,132(M)
Technical analysis
2024-06-12 4:23:49 PM
Short term     
Mid term     
Targets 6-month :  28.19 1-year :  30.3
Resists First :  24.14 Second :  25.95
Pivot price 22.78
Supports First :  21.21 Second :  17.65
MAs MA(5) :  22.53 MA(20) :  23.28
MA(100) :  21.8 MA(250) :  19.88
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  39.7 D(3) :  25.8
RSI RSI(14): 58.4
52-week High :  25.95 Low :  13.81
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MYGN ] has closed below upper band by 13.7%. Bollinger Bands are 46.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 24.3 - 24.39 24.39 - 24.5
Low: 22.72 - 22.82 22.82 - 22.92
Close: 23.4 - 23.57 23.57 - 23.75
Company Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Headline News

Wed, 12 Jun 2024
Myriad Genetics (NASDAQ:MYGN) Shares Gap Up to $22.47 - MarketBeat

Wed, 12 Jun 2024
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing - Zacks Investment Research

Tue, 11 Jun 2024
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries - GlobeNewswire

Sat, 08 Jun 2024
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings? - Yahoo Movies UK

Tue, 04 Jun 2024
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen - Yahoo Finance

Thu, 16 May 2024
Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN) - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 91 (M)
Shares Float 71 (M)
Held by Insiders 2 (%)
Held by Institutions 105.8 (%)
Shares Short 5,100 (K)
Shares Short P.Month 5,500 (K)
Stock Financials
EPS -2.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.39
Profit Margin -30.3 %
Operating Margin -13.9 %
Return on Assets (ttm) -6.6 %
Return on Equity (ttm) -29.5 %
Qtrly Rev. Growth 11.6 %
Gross Profit (p.s.) 0
Sales Per Share 8.55
EBITDA (p.s.) -0.75
Qtrly Earnings Growth 0 %
Operating Cash Flow -96 (M)
Levered Free Cash Flow -37 (M)
Stock Valuations
PE Ratio -8.42
PEG Ratio -90.7
Price to Book value 2.8
Price to Sales 2.75
Price to Cash Flow -22.15
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android